Sarborg's Quantum Leap: Reshaping Pharma IP and Drug Development

NAPLES, Fla. and CAMBRIDGE, United Kingdom – June 26, 2026 – In a move that signals a significant shift in pharmaceutical R&D, CDT Equity Inc. (NASDAQ: CDT) has highlighted a major technological advance from its portfolio company, Sarborg Limited. Sarborg is deploying quantum computing to revolutionize one of the most challenging aspects of drug creation: solid-form development. The initiative, spearheaded by Sarborg's dedicated quantum division SarborgQ, integrates agentic AI and proprietary data to accelerate the discovery of new drug formulations and, crucially, new intellectual property.

This development is more than just a technical milestone; it’s a strategic play that underscores CDT Equity’s model of investing in data-driven, platform-based innovation. By applying quantum mechanics to the granular chemistry of drug design, Sarborg aims to solve problems that have long stumped conventional methods, potentially unlocking immense value.

“We are pleased to see Sarborg continuing to execute against its strategic roadmap and further expand the practical applications of its Signature Intelligence platform,” said Andrew Regan, Chief Executive Officer of CDT Equity. “The application of SarborgQ to solid-form development demonstrates how Sarborg is seeking to leverage quantum computing to accelerate intellectual property generation and strengthen the commercial potential of its existing asset portfolio, whilst also creating opportunities to support third-party development programmes.”

The Quantum Frontier in Drug Formulation

For decades, the high cost and glacial pace of pharmaceutical development have been accepted as industry constants. Quantum computing promises to shatter that paradigm. Unlike classical computers that process information in bits (0s or 1s), quantum machines use qubits, which can exist in multiple states simultaneously—a principle called superposition. This allows them to analyze a vast number of possibilities at once, making them exceptionally suited for modeling the complex, probabilistic world of molecular interactions.

In drug development, this capability is transformative. Solid-form development—the process of finding the optimal crystal structure for a drug molecule to ensure its stability, solubility, and effective delivery in the body—is a critical and often-frustrating bottleneck. A staggering 80-90% of new drug candidates exhibit poor solubility, hindering their path to market. SarborgQ is targeting this exact problem. By using quantum-assisted tools, it can more accurately predict how different molecules, known as coformers, will interact to create stable, effective drug forms called co-crystals.

While the field is still nascent, with challenges like hardware noise and scalability, the industry is moving toward hybrid quantum-classical workflows. Here, classical supercomputers manage broader tasks while quantum processors tackle the specific, complex calculations where they have an edge. This pragmatic approach is already bearing fruit, with major tech players like IBM and Google partnering with pharmaceutical giants to simulate molecules at a scale previously unimaginable. Sarborg's move places it squarely at the forefront of this practical application, moving quantum computing from a theoretical advantage to a tangible R&D tool.

A New Engine for Intellectual Property

At the heart of Sarborg’s initiative is its Signature Intelligence platform, an ecosystem combining three powerful elements: a curated, proprietary database of over 850 coformers; an "agentic AI architecture" that can reason and make decisions; and now, the raw computational power of SarborgQ. This synergy is designed not just to find better drug forms, but to find them faster and identify novel configurations that can be patented.

The commercial implications are profound. In the pharmaceutical industry, intellectual property is the ultimate currency. A strong patent on a new solid form can extend a drug's market exclusivity, protect it from generic competition, and create a durable revenue stream. By accelerating the identification of these patentable assets, Sarborg's platform becomes a powerful engine for value creation.

The company's strategy is twofold. Internally, it will deploy SarborgQ across its own IP portfolio to enhance existing products and generate new, defensible assets. Externally, it plans to offer these capabilities as a service to other pharmaceutical companies, tapping into a massive market. With the global drug formulation market projected to reach nearly €3 trillion by 2032, and with formulation failures costing the European industry billions annually, the demand for a solution that improves efficiency and success rates is immense. For CDT Equity, this dual strategy validates its investment thesis: backing platform technologies that can generate internal value while also creating a scalable, high-margin service business.

Navigating the Uncharted Regulatory and Economic Waters

The introduction of such a disruptive technology inevitably raises complex questions. Regulatory bodies like the U.S. Food and Drug Administration (FDA) are already working to establish frameworks for AI and machine learning in drug development. Quantum-assisted methods will likely fall under these evolving guidelines, requiring companies like Sarborg to demonstrate not only the efficacy of their discoveries but also the validity and transparency of the computational processes that produced them.

Furthermore, the reliance on "proprietary datasets" and "agentic AI" touches on critical issues of data governance and algorithmic accountability. As these systems become more autonomous, ensuring they are free from bias and that the data they use is handled ethically will be paramount. The immense power of quantum computing to process, and potentially decrypt, vast datasets introduces new imperatives for data security and privacy.

This technological arms race also reshapes the competitive landscape. As quantum tools become more accessible, the ability to generate novel intellectual property could accelerate dramatically, leading to an even more intense "Race for Novel IP." This may trigger new legal and strategic challenges around the patentability of discoveries made by AI and quantum systems. For investors and industry players, CDT Equity's backing of SarborgQ is a clear signal that the future of biopharmaceutical value creation lies at the intersection of deep scientific expertise, powerful data platforms, and the paradigm-shifting potential of quantum computing.